VedaBio IncFinancing/PartneringSiemens Healthineers enters CRISPR diagnostics spaceSiemens Healthineers have participated in a US$25m Series A extension of the CRISPR diagnostics specialist VedaBio Inc and signed a strategic agreement. more ➔
Peter de Klerk from Must n Stum/PRNewsfoto/Revyvealternative proteinRevyve scaling up production by €24m financingWageningen-based food-tech scale-up Revyve has raised €24m in a Series B financing, bringing its total capital raised to more than €40 million. The company will use the proceeds to scale up its yeast-based … more ➔
Roche AGObesityRoche moves obesity asset CT-388 into Phase IIISwiss Roche AG will advance its injectable obesity lead CT-388 into Phase III studies starting in H1/2026. With combination therapies, the Swiss pharma major aims at becoming obesity company No. 3 by … more ➔
MAES-AREA-EnglosRestructuringGenfit SA discontinues lead programmeLille-based Genfit SA has discontinued Phase II development of its lead drug candidate VS-01, a liposomal ammonia scavenger designed to prevent organ failure in acute chronic liver failure (ACLF). The … more ➔
wikipedia - PyMOL rendering of PDBFinancingMondego Bio kicks off with Series A financingLisbon’s immuno-oncology company Mondego Bio Lda has left stealth mode through a Series A financing led by Biovance Capital, supported by OrbiMed and Torrey Pines. more ➔
Henk Vrieselaar - stock.adobe.com M&ARoche acquires 89bio for US$3.5bnRoche has signed a definitive merger agreement to acquire 89bio and its Phase III candidate pegozafermin, an FGF21 analogue for the treatment of moderate to severe metabolic dysfunction-associated steatohepatitis … more ➔
Adobe stock photos - nadiaPartnershipCSL backs VarmX in US$2.2bn dealCSL has signed an option and collaboration agreement with VarmX valued at up to US$2.2bn. The company will pay US$117m upfront and will fund a global Phase III trial of VMX-C001. more ➔
adobe stock photos - kemolSeries A financingEnhanced Genomics raises US$19mBritish Enhanced Genomics Ltd has extended its Series A funding to US$19m. Investors include BGF, Parkwalk, and Meltwind. more ➔
Rosa Therapeutics IncPartnershipsMonte Rosa Therapeutics and Novartis agree on second billion-dollar dealMonte Rosa Therapeutics Inc, founded in Basel in 2018, can look forward to an upfront payment of US$120m for its second collaboration and licensing deal with Novartis AG to develop protein degraders. … more ➔
FDADrug evaluationTrump dismantles FDA expert committeesThe FDA under President Trump is heading for a radical break with decades of practice: the external advisory committees that have long served as critical checks in approval decisions are to be largely … more ➔
VedaBio Inc
Peter de Klerk from Must n Stum/PRNewsfoto/Revyve
Roche AG
MAES-AREA-Englos
wikipedia - PyMOL rendering of PDB
Henk Vrieselaar - stock.adobe.com 
Adobe stock photos - nadia
adobe stock photos - kemol
Rosa Therapeutics Inc
FDA